Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease
1
Coral Ridge Medical Center, 821 Coral Ridge Drive, Coral Springs, FL 33065, USA
2
MD Stem Cells, 3 Sylvan Road South, Westport, CT 06880, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Tadayuki Akagi
Medicines 2021, 8(2), 10; https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8020010
Received: 22 December 2020 / Revised: 23 January 2021 / Accepted: 25 January 2021 / Published: 3 February 2021
(This article belongs to the Special Issue Stem Cells in Eye Research and Ophthalmology—Current Advances and Future Directions)
Background: Stargardt Disease is the most common inherited macular degeneration, typically resulting in progressive central vision loss and legal blindness at an early age. We report regarding 34 eyes with Stargardt Disease treated in the Stem Cell Ophthalmology Treatment Study (SCOTS and SCOTS2). Methods: Autologous bone marrow was processed, separating the stem cell fraction which was provided Arms using retrobulbar, subtenons, intravitreal or subretinal and intravenous. The follow-up period was one year. Results: Of the 34 treated eyes, 21 (61.8%) improved, 8 (23.5%) remained stable, and 5 (14.7%) showed continued progression of their disease. Results were statistically significant with p = 0.0004. The average central vision improvement following treatment was 17.96% (95%CI, 16.39–19.53%) and ranged up to 80.5%. Of 17 patients treated, 13 (76.5%) showed visual acuity improvement in one or both eyes, 3 patients (17.6%) showed no net loss, and 1 worsened as a consequence of disease progression; 94.1% of patients had improved vision or remained stable. There were no adverse events. Conclusions: Patients with Stargardt Disease may potentially benefit from autologous bone marrow-derived stem cells (BMSC) as provided in SCOTS. Improvement or stabilization of vision was found to occur for the vast majority of reported patients and findings were highly statistically significant.
View Full-Text
Keywords:
Stargardt Disease; macular degeneration; SGDT1; bone marrow-derived stem cells; BMSC; stem cells; hereditary maculopathy; juvenile macular degeneration; hereditary macular degeneration; ABCA4 mutation
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Weiss, J.N.; Levy, S. Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease. Medicines 2021, 8, 10. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8020010
AMA Style
Weiss JN, Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease. Medicines. 2021; 8(2):10. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8020010
Chicago/Turabian StyleWeiss, Jeffrey N., and Steven Levy. 2021. "Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease" Medicines 8, no. 2: 10. https://0-doi-org.brum.beds.ac.uk/10.3390/medicines8020010
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
